Mabo Farma
Mabo Farma is a Spanish pharmaceutical laboratory (founded 1997, Madrid) that manufactures generic medications across 12 therapeutic areas and operates the MABONATUR premium food supplement and therapeutic cosmetics brand, distributed primarily through Spanish pharmacies and DTC e-commerce. Since 2023 it has been a subsidiary of PharmaS Group.
- Company typePrivate
- Founded1997
- HeadquartersCoslada, Spain
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What Mabo Farma does
Mabo Farma (MABO FARMA S.A.) is a Spanish pharmaceutical laboratory founded in 1997 and headquartered in Madrid, operating a dual-brand portfolio in two adjacent categories. The MABOFARMA brand comprises a broad range of generic pharmaceutical medications (Especialistas en Medicamentos Genéricos) spanning 12 therapeutic areas — anti-infective, anti-inflammatory/analgesic, digestive, cardiovascular, ophthalmological, oncological, osteoarticular, respiratory, mental health, CNS, urological, and OTC — with approximately 80+ branded generic SKUs (e.g., Omeprazol Mabo, Paracetamol Mabo, Atorvastatina Mabo, Escitalopram Mabo). The MABONATUR sub-brand offers 40+ premium food supplements and therapeutic cosmetics across digestive, immune, bone and joint, cardiovascular, women's health, urinary, magnesium, and sleep/relaxation categories, with recent innovations including the 100% Organic Magnesium line (citrate, malate, glycinate) and the PROBalans OmniBoost symbiotic probiotic formula.
Manufacturing is certified to EU GMP, HACCP, and CFR21 quality standards. Since 2023, Mabo Farma has operated as part of PharmaS Group, an international pharmaceutical conglomerate with presence in 12 countries, 3 manufacturing facilities, approximately 500 employees globally, and production capacity of roughly 30 million products per year. The business model is dual-channel: generic medications are dispensed through Spanish pharmacies under National Code (CN) identification, while Mabonatur products are sold exclusively through pharmacies supplemented by direct-to-consumer e-commerce at mabonatur.com. The company supports its pharmacy channel with HCP education programs (Mabo Talks, Espacio Farma), a 60,000+ subscriber email newsletter, and active social media presence. Pricing is not publicly disclosed, and revenue figures are not available in the source material.
Mabo Farma firmographics
Firmographics- Name
- Mabo Farma
- Legal name
- MABO FARMA S.A.
- Website
- https://mabofarma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Mabo Farma is a Spanish pharmaceutical laboratory (founded 1997, Madrid) that manufactures generic medications across 12 therapeutic areas and operates the MABONATUR premium food supplement and therapeutic cosmetics brand, distributed primarily through Spanish pharmacies and DTC e-commerce. Since 2023 it has been a subsidiary of PharmaS Group.
- Ownership category
- akta.pro rank
Mabo Farma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Mabo Farma is headquartered
LocationHeadquarters
- HQ city
- Coslada
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Mabo Farma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Medications (EFG): Mabo Farma produces and sells generic pharmaceutical products (Especialistas en Medicamentos Genéricos) across multiple therapeutic areas including cardiovascular, mental health, anti-inflammatory, digestive, respiratory, and more. Products include branded generics like Omeprazol Mabo, Paracetamol Mabo, Amlodipino Mabo, etc.
- Mabonatur Food Supplements: Premium food supplements and therapeutic cosmetics sold exclusively through pharmacies and direct-to-consumer e-commerce. Product lines include probiotics, magnesium supplements, vitamins, minerals, herbal extracts, collagen products, andCBD-based products.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Mabo Farma product offering
Product offeringCore offering
Mabo Farma manufactures and sells a broad portfolio of generic pharmaceutical medications (EFG) covering cardiovascular, mental health, anti-inflammatory, digestive, respiratory, and other therapeutic areas. Under its MABONATUR sub-brand, it also produces and markets premium food supplements and therapeutic cosmetics (probiotics, magnesium, vitamins, herbal extracts, collagen, CBD creams) sold exclusively through pharmacies and a direct-to-consumer e-commerce store.
Product overview
Mabo Farma operates as a dual-brand pharmaceutical company with two distinct product lines: (1) MABOFARMA Generic Medications - a comprehensive portfolio of generic pharmaceutical drugs covering 12 therapeutic areas (ANTIINFECCIOSA, ANTIINFLAMATORIA ANALGÉSICA, DIGESTIVO, CARDIOVASCULAR, OFTALMOLÓGICA, ONCOLÓGICA, OSTEOARTICULAR, RESPIRATORIO, SALUD MENTAL, SNC, UROLOGÍA, and OTC) including approximately 80+ products such as cardiovascular medications (Amlodipino, Atorvastatina, Losartán), CNS medications (Alprazolam, Escitalopram, Venlafaxina), gastrointestinal medications (Esomeprazol, Lansoprazol, Omeprazol), pain/inflammation medications (Ibuprofeno, Dexketoprofeno), and many others; and (2) MABONATUR - a premium food supplement and therapeutic cosmetics sub-brand offering 40+ products across therapeutic categories including cardiovascular (MABOLIPID, MABOFERRO), bones & joints (MABOFLEX line with multiple variants, K2 & D3), digestive health (MABOBÍFIDUS probiotics, DIGESTIN ENZYMES, PROBalans® OmniBoost, GASTROMABO), immune support (MABODEFENSAS, PROBETAGLUKAN®, INMUNO C D© FORTE, ALIBRA), women's health (FEMIPAUSE, FÓLICO ACTIVO QUATREFOLIC), urinary health (MABOCYST D-mannose products), magnesium supplements (MAGNESIO CITRATO, MALATO, GLICINATO - 100% organic), sleep/relaxation (MABO SUEÑO, MABO MELATONINA KIDS, TRIPTÓFANO), and therapeutic cosmetics (MABODOL CBD cream, MABODERM line). The company emphasizes Science and Conscience ('Ciencia y Conciencia') in product development, using rigorously selected active ingredients backed by clinical studies, with EU GMP, HACCP, and CFR21 certified manufacturing. Since 2023, Mabo Farma is part of the international PharmaS Group.
Differentiator
Problem solved
Functional benefit
Brands
- MABONATUR: Premium food supplements and therapeutic cosmetics line designed to offer the best of nature and science for pharmaceutical recommendation.
Products and services
- MABOFARMA Generic Medications (EFG)
Quantifiable outcome
- 80% of population takes less magnesium than recommended (ANIBES study cited)
Companies that use Mabo Farma
Customer profileSegments2 records
Ideal customer profiles2 records
Mabo Farma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Mabo Farma partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Mabo Farma competitors and assessment
Company assessmentDirect peers
- Arkopharma: French pharmaceutical laboratory specializing in natural and botanical food supplements sold primarily through pharmacies; directly comparable to Mabo Farma's MABONATUR line on category, formulation approach, and pharmacy-exclusive distribution.
- Ratiopharm: German generics brand now part of Teva, with broad European generics distribution; comparable to Mabo Farma as a multi-country generics manufacturer with strong pharmacy-channel presence across Europe.
- Cinfa: Spanish generic pharmaceutical manufacturer headquartered in Pamplona with a broad portfolio across cardiovascular, CNS, and other therapeutic areas, distributing primarily through Spanish pharmacies — directly comparable in scale, channel, and product breadth to Mabo Farma.
- Kern Pharma: Barcelona-based Spanish generics laboratory with a comprehensive EFG portfolio and growing consumer health / biosimilars presence; comparable to Mabo Farma in generics focus, therapeutic breadth, and pharmacy distribution.
- Normon: Spanish generic pharmaceutical laboratory headquartered in Tres Cantos (Madrid) producing a wide portfolio of oral solid and injectable generics distributed through pharmacies — directly comparable to Mabo Farma on geography, category, and channel.
Regional players
- Almirall: Spanish pharmaceutical company headquartered in Barcelona with a focus on dermatology and specialty products; comparable as a Spain-based pharma peer but differentiated by therapeutic focus and prescription-led rather than OTC/supplement-led model.
Broad incumbents
- Sandoz: Novartis' generics and biosimilars division with extensive European operations; competes with Mabo Farma across generic categories and increasingly in differentiated generics and consumer health adjacencies.
- Viatris: Global pharmaceutical company formed from Mylan and Pfizer's Upjohn, with a substantial generics portfolio across European markets; competes with Mabo Farma in established generic molecules while operating at significantly larger scale.
- Stada Arzneimittel: German-headquartered European generics and consumer healthcare company with a strong pharmacy-channel portfolio; comparable to Mabo Farma on combining generics with branded consumer health products sold through pharmacies.
- Teva Pharmaceutical Industries: Global leader in generic medicines with a deep Spanish and European footprint; a broad incumbent competing against Mabo Farma across multiple generic molecules while also offering specialty and biosimilar products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Mabo Farma social profiles
Digital presenceMabo Farma compliance and trust
Trust signalCompliance3 records
Mabo Farma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mabo Farma leadership team
Management profileNumber of profiles
Profiles5 records
Mabo Farma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mabo Farma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mabo Farma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mabo Farma
What does Mabo Farma do?
Mabo Farma manufactures and sells a broad portfolio of generic pharmaceutical medications (EFG) covering cardiovascular, mental health, anti-inflammatory, digestive, respiratory, and other therapeutic areas. Under its MABONATUR sub-brand, it also produces and markets premium food supplements and therapeutic cosmetics (probiotics, magnesium, vitamins, herbal extracts, collagen, CBD creams) sold exclusively through pharmacies and a direct-to-consumer e-commerce store.
Is Mabo Farma a public or private company?
Mabo Farma is a private company. It is classified as corporate owned and is currently operating.
When was Mabo Farma founded?
Mabo Farma was founded in 1997. It employs 51 to 100 people.
Where is Mabo Farma based?
Mabo Farma is headquartered in Coslada, Spain, in the Europe region.
How does Mabo Farma make money?
Two revenue lines are on record. Generic Medications (EFG) is the primary driver. The others are mabonatur Food Supplements.
Who are Mabo Farma's main competitors?
Direct peers on record are Arkopharma, Ratiopharm, Cinfa, Kern Pharma and Normon. Almirall is listed as a regional player. Broad incumbents are Sandoz, Viatris, Stada Arzneimittel and Teva Pharmaceutical Industries.
Does Mabo Farma have an API?
No public API is recorded for Mabo Farma.
What industry is Mabo Farma in?
Mabo Farma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2833.